Request Demo

Last update 08 May 2025

Spiramycin/Metronidazole

Last update 08 May 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Spirazole forte

Target

DNA

Action

inhibitors

Mechanism

DNA inhibitors(DNA inhibitors)

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC43H74N2O14

InChIKeyACTOXUHEUCPTEW-CEUOBAOPSA-N

CAS Registry24916-50-5

View All Structures (2)

Clinical Trials associated with Spiramycin/Metronidazole

NCT05222737

/ CompletedPhase 2/3IIT

Quantitave Assessment of Aggregatibacter Actinomycetemcomitans and Porphyromonas Gingivalis by Real -Time PCR Following Application of Diode Laser in Severe Periodontitis (A RANDIOMIZED CONTROLLED CLINICAL TRIAL)

Primary objective To measure the gingival crevicular levels of A.actinomycetemcomitans and P.gingivalis after intra-pocket application of diode laser in severe periodontitis (stage 3 grade C) patients.
Secondary objective To compare the levels of the same microorganisms as in cases of diode laser therapy to those after conventional treatment with systemic antibiotic administration in severe periodontitis (stage 3 grade C) patients.
to measure clinical parameters probing depth,attachment loss and mobility grade

Start Date01 Jan 2021

Sponsor / Collaborator

Alexandria University

100 Clinical Results associated with Spiramycin/Metronidazole

100 Translational Medicine associated with Spiramycin/Metronidazole

100 Patents (Medical) associated with Spiramycin/Metronidazole

Literatures (Medical) associated with Spiramycin/Metronidazole

01 Apr 2020·Heliyon

Effect of nitazoxanide and spiramycin metronidazole combination in acute experimental toxoplasmosis

Article

Author: Farag, Hoda Fahmy ; Shehab, Amel Youssef ; Fawzy Hussein Mogahed, Nerrmine Mogahed ; Elsayed, Yasmen ; FarahatAllam, Amal ; Abd El-Latif, Naglaa Fathi

Successful treatment of Toxoplasma gondii infection is difficult to attain. This study was designed to evaluate the efficacy of sulfamethoxazole-trimethoprim (SMZ-TMP), as the reference drug, nitazoxanide (NTZ), spiramycin (SP) and SP-metronidazole against the virulent RH T. gondii strain in acute experimental toxoplasmosis. One hundred Swiss albino mice were divided into control and experimental groups. Each mouse was infected with 2500 tachyzoites. Twenty infected untreated mice were used as control. The experimental group was subdivided into four subgroups (20 mice each); IIa SMZ-TMP, IIb NTZ, IIc SP and IId SP-metronidazole. All drugs were in tablet form, and were administered orally in suspension, for a period of seven days. Assessment of each drug efficacy was achieved through the study of mice survival time, mortality rate, parasite load, viability and morphological studies of tachyzoites by scanning electron microscope (SEM). The obtained results showed that SMZ-TMP, SP and SP-metronidazole were effective against acute murine toxoplasmosis and caused deformities in the tachyzoites ultrastructure. SP-metronidazole gave the best results on both mice survival rate and parasite load in the brain and liver. SMZ-TMP induced formation of prominent filaments extending from the deformed tachyzoites. NTZ showed little effect. In conclusion, all used drugs succeeded to prolong the survival time of the mice. SP-metronidazole gave the foremost effect on both mice survival rate and parasite load in the liver, spleen and brain. As this combination is nontoxic to human, it is promising for the treatment of human toxoplasmosis.

01 Oct 1981·Journal of Small Animal PracticeQ3 · AGRICULTURAL & FORESTRY SCIENCE

Haemobartonella canis(Kiküth, 1928) in the blood of dogs with parvovirus disease

Q3 · AGRICULTURAL & FORESTRY SCIENCE

Article

Author: Simon Gretillat

ABSTRACTIn the Tours area of the Val‐de Loire, haemograms carried out in 40 dogs with canine parvovirus disease showed that in 30 cases the viral infection was complicated by canine haemobartonellosis. To the picture, typical of the former infection, were added very severe anaemia, fever, locomotor difficulties, arthralgia, adenopathy, respiratory difficulties (dyspnoea, polypnoea and anoxia) and circulatory disorders (tachycardia and capillary fragility). The blood picture was markedly abnormal, anisocytosis, poikilocytosis and anisochromia, being found together with alterations in the blood counts (neutrophils 85 to 90% high; leucocytes, 400 to 500 mm3; erythrocytes, 0·6 to 1·5 × 106mm3).Symptomatic treatment and serotherapy (equine hyperimmune serum against feline panleucopenia) were given for the parvovirus infection. Of the antimicrobial agents, only chloramphenicol, a spiramycin metronidazole association and sulphamethoxypyridazine gave good results.A high dose of intramuscular chlorpromazine (2 to 4 mg/kg b.w.) repeated 48 h later, followed by an 8‐day course of oral treatment at a moderate dosage (1 mg/kg b.w. daily) produced complete clinical cure and disappearance ofHaemobartonella canisfrom the peripheral blood.It is considered that these results support the view that an intercurrent infection may upset the balance existing between the host and parasite in carriers ofH. canisand produce a virulent infection (see Fig. 1).

100 Deals associated with Spiramycin/Metronidazole

R&D Status

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Spiramycin/Metronidazole

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation